💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ticlopidine

CHEMBL833 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
263.8 g/mol
LogP
3.6
Phase
4

This antiplatelet medication reduces the risk of stroke in patients who have had a previous stroke or TIA (mini-stroke) and cannot take aspirin. It works by blocking ADP-mediated platelet aggregation, preventing blood clots from forming. Its use has declined due to serious side effects including low white blood cell count and a rare but dangerous blood disorder (TTP), and it has largely been replaced by newer agents.

Молекулярная масса

263,8000 g/mol

LogP

3,60

TPSA

31,50 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Pancreatic Cancer Cardiovascular Disease Age-Related Macular Degeneration Asthma Chronic Obstructive Pulmonary Disease Migraine Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Major Depressive Disorder HIV/AIDS Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Clc1ccccc1CN1CCc2sccc2C1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H14ClNS

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
Вращаемые Связи

                        
2

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This antiplatelet medication reduces the risk of stroke in patients who have had a previous stroke or TIA (mini-stroke) and cannot take aspirin. It works by blocking ADP-mediated platelet aggregation, preventing blood clots from forming. Its use has declined due to serious side effects including low white blood cell count and a rare but dangerous blood disorder (TTP), and it has largely been replaced by newer agents.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Ticlopidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL833.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5472.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.